Overview

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Status:
Not yet recruiting
Trial end date:
2025-05-13
Target enrollment:
Participant gender:
Summary
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company